Cytarabine and Poor venous access - a phase IV clinical study of FDA data

Summary:

Poor venous access is reported as a side effect among people who take Cytarabine (cytarabine), especially for people who are female, 20-29 old, have been taking the drug for 1 - 6 months also take Augmentin '125', and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Poor venous access when taking Cytarabine. It is created by eHealthMe based on reports of 65,319 people who have side effects when taking Cytarabine from the FDA, and is updated regularly.

What is Cytarabine?

Cytarabine has active ingredients of cytarabine. It is often used in acute myelogenous leukemia (aml) - adult. eHealthMe is studying from 65,358 Cytarabine users. Check the latest studies of Cytarabine.

What is Poor venous access?

Poor venous access is found to be associated with 678 drugs and 481 conditions by eHealthMe. Check the latest studies of Poor venous access.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

65,319 people reported to have side effects when taking Cytarabine.
Among them, 16 people (0.02%) have Poor venous access.

Could Cytarabine cause Poor venous access?

Among these 16 people:

How long have people been on Cytarabine when they have Poor venous access? *

What is the gender of people who have Poor venous access when taking Cytarabine? *

female: 81.25 %
male: 18.75 %

What is the age of people who have Poor venous access when taking Cytarabine? *

What are other drugs people take besides Cytarabine? *

Chlorhexidine Gluconate: 3 people, 18.75%
Proscar: 3 people, 18.75%
Pred Forte: 3 people, 18.75%
Peridex: 3 people, 18.75%
Amoxicillin: 3 people, 18.75%
Neulasta: 3 people, 18.75%
Aranesp: 3 people, 18.75%
Atenolol: 3 people, 18.75%
Augmentin '125': 3 people, 18.75%
Zosyn: 2 people, 12.50%

What are other side effects people have besides Poor venous access? *

Oedema Peripheral (superficial swelling): 12 people, 75.00%
Drug Intolerance (drug sensitivity): 10 people, 62.50%
Weight Increased: 10 people, 62.50%
Renal Impairment (severely reduced kidney function): 10 people, 62.50%
Blast Crisis In Myelogenous Leukaemia: 10 people, 62.50%
Rashes (redness): 10 people, 62.50%
Mood Swings (an extreme or rapid change in mood): 10 people, 62.50%
Cardiac Failure: 10 people, 62.50%
Neutropenic Sepsis (whole body infection is caused by a condition in which the number of white blood cells (called neutrophils) in the blood is low. neutrophils help the body to fight infection): 10 people, 62.50%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 8 people, 50.00%

What are the existing conditions these people have? *

Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 9 people, 56.25%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 9 people, 56.25%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 18.75%
Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Cytarabine and have Poor venous access?

- Check whether Poor venous access is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cytarabine:

Cytarabine (65,358 reports)

Browse all side effects of Cytarabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Poor venous access:

Poor venous access (678 drugs)

Browse all the conditions that are associated with Poor venous access:

Poor venous access (481 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cytarabine (the active ingredients of Cytarabine) and Cytarabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.